Physician profile
Michael Douglas
NPI 1932296373
$1,542.55
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $285 · 2023: $34.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $287.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $160.51 | 2019-2020 | |
| Pfizer INC. | $133.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $113.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $108.18 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.34 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $78.45 | 2019-2020 | |
| Amarin Pharma, INC. | $60.14 | 2019-2020 | |
| Amgen INC. | $58.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.51 | 2019-2020 | |
| Lilly USA, LLC | $50.29 | 2019-2020 | |
| Allergan, INC. | $47.81 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $46.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.41 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $34.89 | 2023 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $28.85 | 2019 | |
| Glaxosmithkline, LLC. | $28.59 | 2019-2020 | |
| Astellas Pharma US INC | $23.68 | 2019 | |
| Mylan Specialty L.P. | $20.90 | 2019 | |
| Dornier Medtech America, INC | $18.57 | 2019 | |
| Abbott Laboratories | $17.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.